Motor neurone disease is a neurodegenerative condition with a signifi cant morbidity and shortened life expectancy. Hypoventilatory respiratory failure is the most common cause of death and respiratory function signifi cantly predicts both survival and quality of life in patients with motor neurone disease. Accordingly, supporting and maintaining respiratory function is important in caring for these patients. The most signifi cant advance in motor neurone disease care of recent years has been the domiciliary provision of non-invasive ventilation for treating respiratory failure. Neuromuscular respiratory weakness also leads to ineffective cough and retained airways secretions, predisposing to recurrent chest infections. In this review, we discuss current practice and recent developments in the respiratory management of motor neurone disease, in terms of ventilatory support and cough augmentation.
Introduction
Motor neurone disease (MND) is a disabling and inevitably fatal disease, usually with a life expectancy of 2-3 years from symptom onset. Pathologically, there is a progressive loss of motor neurones, resulting in weakness and atrophy of skeletal and bulbar muscles. It is the third most common neurodegenerative disease of adults, often affecting fit and active people. It tends to develop in later life, with an average age of onset of 55-60 years. The life-time risk is 1 in 1000, affecting 5-7 per 100 000 at any time. Most cases are sporadic, but 5-10% are familial. MND is incurable and there are few treatments that alter survival. Riluzole, the only licensed neuroprotective drug, improves survival by an average of 3-4 months. Without a significant disease-modifying drug, the main emphasis is on symptom management to maintain a good quality of life. Thus, non-invasive support of respiratory function has significantly advanced the care of MND patients. This article describes the up-to-date management of common respiratory symptoms, while highlighting recent developments and the scope for future research.
Mechanics of breathing and its disturbance in MND
The inspiratory muscles-the diaphragm, intercostal and accessory muscles-perform the main work of ventilation. Expiration is largely passive, through elastic recoil of the lungs and rib cage. Normal ventilation requires both an adequate central nervous system drive and good ventilatory muscle function to overcome the respiratory load. The respiratory load is a combination of inspiratory flow resistance, elastic resistance of the lungs and chest wall, and the positive pressure within the air spaces (peak end expiratory pressure). In healthy lungs, inspiratory muscle contraction generates a negative force greater than the respiratory load and so air enters the lungs. Voluntary control from the cerebral cortex can override spontaneous breathing, allowing a modified pattern of breathing such as in breath holding, coughing, Valsalva manoeuvre, etc.
In MND, there are fewer motor units within the respiratory muscles, reducing their force of contraction, and giving them less capacity to overcome the respiratory load. Interruption of the descending upper motor neurone input from the cortex impairs the voluntary control of breathing. Abnormal central respiratory drive may also contribute to the respiratory dysfunction in MND. 1 
Clinical features of respiratory impairment in MND
Sleep often initially unmasks respiratory muscle weakness, and particularly, rapid eye movement (REM) sleep. During REM sleep, there is hypotonia of the intercostal and accessory muscles and also depressed central respiratory drive. Thus, the diaphragm, weakened by partial denervation yet working alone, may not generate enough pressure to overcome the respiratory load, causing hypoventilation. Therefore, the patient must wake frequently from REM sleep to maintain adequate ventilation. Sleep-disordered breathing (SDB) is one of the earliest manifestations of respiratory insufficiency. 2 Patients with SDB experience early morning headaches, unrefreshing sleep and daytime somnolence. A partner's or carer's history can help as they may be more aware than the patient of frequent arousals from sleep. Orthopnoea is another early symptom of diaphragmatic weakness: clinicians should ask about the number of pillows used in bed. Every patient with MND should be assessed for the symptoms of respiratory impairment (table 1) . Postural discomfort, cough and excessive saliva may also disturb sleep in MND, and so, produce sleep-related symptoms. Poor bulbar function also disrupts sleep through hypotonia and collapse of the upper airway musculature, especially during REM sleep. It is important to establish the precise cause of disturbed sleep, to provide the correct treatment. Respiratory muscle weakness usually develops insidiously, but can occur suddenly, rarely being the presenting feature. 3 In patients presenting with sudden onset respiratory symptoms, it is important to remember the possibility of intercurrent events such as chest infection, pulmonary embolism and increasing obesity. Some patients have significant hypoventilation and hypercapnia without major symptoms. Moreover, the early symptoms of respiratory failure are often non-specific and may overlap with symptoms common in MND, such as fatigue and tiredness. Therefore, the clinical assessment should include one or more respiratory function tests (see below).
Non-invasive ventilation
Having identified hypoventilation and hypercapnia, it may be appropriate to offer non-invasive ventilation (NIV). NIV improves gas exchange, alleviating symptoms of CO 2 retention. A recent Cochrane review concluded that NIV significantly improves quality of life and prolongs survival in people with MND. 4 This conclusion was largely based on the only randomised controlled trial of NIV in patients with MND. 5 In this study, MND patients were allocated either to NIV or to standard care without NIV. In the NIV group (n=22), median survival was 48 days (p=0.0062, 95% CI 12 to 91 days) longer than in the standard care group (n=19). In the subgroup of patients with good or moderate bulbar function, median survival was 205 days longer (p=0.0059). The subgroup with poor bulbar function had no survival advantage. The authors measured the number of days that patients maintained a quality of life score >75% of their baseline. In the whole NIV group, the mental component summary of the SF36 and the sleep apnoea quality of life index domains remained above 75% for longer than in the standard care group. Thus, the increased survival with NIV was not at the expense of quality of life.
How does NIV work?
The exact mechanism by which NIV improves survival in MND patients is uncertain. There are several possibilities, including reversing chronic respiratory muscle fatigue ■ by reducing work of breathing, so improving oxygenation and cellular metabolism; reversing hypercapnia, so improving central NIV may also slow the decline of forced vital capacity (FVC) in patients with MND. The decision to start NIV requires considerable skill and experience, taking into account several factors: the patient's wishes and circumstances; symptoms and signs of respiratory insufficiency; respiratory function tests and rate of progression of MND. In a recent survey on the current UK practice of NIV in motor neurone disease, 32% of neurologists relied on symptoms only; 43% used both symptoms and respiratory function tests; and 10% offered NIV based on abnormal respiratory function tests, with minimal or no symptoms. 7 Offering NIV on investigations alone (eg, any of FVC <50% of predicted, maximal inspiratory pressure/sniff nasal inspiratory pressure <40 cm H 2 O, PaCO 2 >6.0 kPa) can be appropriate without apparent sleep-related symptoms, since almost all such patients have significant oxygen desaturations on overnight oximetry. 8 9 The National Institute for Health and Clinical Excellence (NICE) has published guidelines on using NIV in patients with MND (http://guidance.nice.org.uk/CG105/Guidance). This recommends respiratory assessment at or near the time of initial diagnosis and repeated every 3 months. The first-line screening tools are enquiry about sleep-related symptoms; Subsequent respiratory function tests include FVC, sniff nasal inspiratory pressure (SNIP) or maximum inspiratory mouth pressure (MIP). The interval between tests depends upon patients' symptoms, signs and rate of disease progression. The guidelines are summarised as a flow chart (figure 1). Note that FVC, SNIP and MIP depend upon the patient's voluntary effort and so may be unreliable in patients with pseudobulbar palsy, who cannot blow or sniff effectively. Patients with facial muscle weakness may not achieve a tight lip seal around the mouthpiece; in this situation, a face mask can help with FVC measurement.
Initiating NIV
Patients need individual assessment for their suitability for NIV. This should include a detailed and sensitive discussion with the patient and carers explaining what NIV involves, and its potential benefits and the limitations (box 1). Patients may defer or decline intervention with NIV if they have mild respiratory symptoms, lack social support or if they do not want a life-prolonging intervention in the face of increasing disability. We emphasise to patients that this intervention not only prolongs life but also improves quality of life. The predictors of a favourable response to NIV include orthopnoea, hypercapnia and nocturnal oxygen desaturations. 10 Those most likely to tolerate NIV include motivated patients with good bulbar and upper limb function and those with a supportive carer.
The form of NIV used in MND is bi-level positive airways pressure (BiPAP), which delivers variable inspiratory and expiratory pressures via a face or nasal mask interface (figure 2). NIV is initially needed only during sleep, although using the mask for a few hours in the day when awake under supervision can help patients build confidence before moving to nocturnal use. The suggested initial settings for patients with MND are 8-10 cm H 2 O for inspiratory positive airway pressure (IPAP) and 4 cm H 2 O for expiratory pressure. 11 The IPAP is subsequently titrated on symptoms and tolerability, while attempting to bring arterial blood gases within the normal range. The interfaces must be comfortable and well-fitted for a patient to tolerate a trial of NIV. They come in various styles, shapes and sizes ( figure 3 ).
There is a range of moulds, materials and fastenings, adjusting the interface systems according to patients' anatomy, comfort and dexterity. Patients often try different interfaces before finding one that is comfortable. Most prefer nasal masks over full face masks as they are less claustrophobic and preserve speech and expectoration of secretions; however, because many MND patients are 'mouth breathers', they are often not suitable. In addition, air leaks are more likely with nasal masks than full-face masks. Table 2 summarises common problems associated with the use of NIV along with some practical solutions. Once established on nighttime ventilation, most patients report more comfortable sleep, improved appetite and performance, and an overall enhanced quality of life. However, with the disease progression, the patient's ventilator needs and the number of hours of assisted ventilation increase. Hence, patients need regular assessment for symptoms of sleep fragmentation and hypercapnia. Oxygen and carbon dioxide measurements can help to ascertain the effectiveness of NIV and whether the ventilator settings need adjustment. Disease progression also brings other problems including increased dependency on the carer, loss of voice, difficulty in swallowing causing malnutrition and excessive drooling of saliva, weak cough causing accumulation of airway secretions, constipation, insomnia and emotional problems. Careful attention to these issues helps to improve the overall quality of life. Community palliative care services can particularly help in the day-to-day management.
Problems associated with NIV
Up to 30% of the patients do not tolerate NIV and stop using it. The reasons include: an uncomfortable mask interface, claustrophobia, eye irritation, skin ulceration from pressure of the mask, mouth dryness, persistent cough or discomfort from retained respiratory secretions, cognitive impairment or difficulty operating the machine. Those with significant bulbar weakness often tolerate NIV poorly. The reasons include air leaks around the mask due to weak oral musculature and poor control of salivary and upper airway secretions. Patients with pseudobulbar palsy have particular difficulty in coordinating their breathing, to synchronise it to the ventilator rhythm. Anticholinergics such as hyoscine butylbromide and atropine may help to control saliva, as may botulinum toxin injection into the salivary glands. 12 Glycopyrrolate infusion may also help saliva control and help patients with bulbar dysfunction to tolerate NIV. 13 An experienced respiratory physiologist can help to alleviate patient anxiety and assist patients in coming to terms with a major life change, while also providing home technical support. An ideal NIV service will offer the patients a 24-h helpline to report any problems. Patients who become increasingly ventilator-dependent (eg, >12 h/day) should have two BiPAP machines, in case of mechanical failure. This avoids unnecessary admissions and reduces patient and carer anxiety.
A major concern with NIV is its safety in patients with severe bulbar weakness, because of the risk that secretions may be blown down an unprotected airway into the trachea and lower airways. In the NIV-randomised controlled trial, the bulbar patient group treated with NIV showed a (nonsignificant) trend to worse survival. However, in another study, bulbar patients showed improved survival, if they were hypercapnic when starting NIV.
14 It is reasonable to try NIV in patients with severe bulbar disease, as, with proper saliva control, they can benefit from improved sleep-related symptoms and correction of hypoventilation. 15 Another concern is offering NIV to patients with a coexistent dementia. Such patients should be assessed on an individual basis regarding their social circumstances, the availability of carers, their ability to give consent and to tolerate NIV. It is particularly important to consider NIV where cognitive problems may be related to respiratory impairment. 
When to stop NIV?
The progressive nature of MND means that over the months, increasing muscle weakness leads to increasing dependence on NIV. Patients begin to use NIV more through the daytime, and inevitably reach a point where NIV no longer provides the necessary ventilation to alleviate symptoms or to correct the blood gas abnormalities. In these circumstances, patients may continue NIV in a palliative sense to ease breathlessness. However, other options may be appropriate, such as withdrawing NIV and end-of-life care.
At the time of assessment and starting NIV, it is important to discuss the expected clinical course and to establish the patient's wishes in relation to using NIV, the treatment of intercurrent illnesses and end-of-life care. These early discussions with the patient and family allow decisions to be made in advance, rather than at a time of crisis. Advanced directives are important as communication becomes increasingly difficult in advanced MND. Any expressed wishes should be clearly documented and communicated to the relevant multidisciplinary team members, to avoid unwanted and inappropriate interventions. When indicated, NIV should be withdrawn with adequate supervision and premedication using a multidisciplinary team approach. 16 This can be done with gradual turning down of the NIV settings, using oxygen, benzodiazipines and opiates to manage any distress. The NICE guidelines for NIV highlight the need for further studies of how to best facilitate and manage the withdrawal of NIV as part of end-of-life care.
Palliative strategies as an alternative to non-invasive ventilation
Palliative care for patients with MND is important throughout the disease process but is crucial 
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in the management of later stages of the disease. 17 Palliative care interventions improve quality of life for both patients and carers. In patients who cannot tolerate NIV, or find NIV no longer effective, death from respiratory failure usually follows within 10-12 weeks. 18 With good palliative care and support of family, most deaths from MND can be peaceful. 19 Opiates, benzodiazepines and oxygen are the most commonly used palliative care measures. Morphine, midazolam and glycopyrrolate, given as a continuous infusion by syringe driver, may maximise symptom control.
Role of cough augmentation
Respiratory muscle weakness not only impairs ventilation but also impairs the ability to generate an effective cough. 20 Cough begins with a deep inspiration and closure of glottis, which then suddenly opens having gained pressure from contraction of the diaphragm, abdominal muscles and expiratory muscles; the cough is then released in the form of a forceful expiration. Cough is an important defence mechanism, clearing the airways from excessive secretions, airborne particles and generating a reflex to prevent aspiration of pharyngeal contents. An inefficient cough predisposes to recurrent chest infections, which is the leading cause of hospital admissions in MND patients. 21 A weak cough is associated with increased choking episodes, which patients find very frightening and perceive as life-threatening. 22 It is important to reassure patients about the recoverable and short-lasting nature of these episodes. If required, lorazepam 1 mg sublingually, can relieve the anxiety.
The strength of an individual's cough can be measured using a peak flow meter with the patient forcibly coughing into a face mask attached to a peak flow meter. Cough effectiveness is suboptimal when peak cough flow (PCF) is <270 l/ min. 23 Pulmonary morbidity and mortality can be reduced by identifying patients with poor PCF and teaching them cough augmentation techniques. 24 Intensive physiotherapy is traditional practice, combined with manoeuvres like tussive squeeze and abdominal thrust (manually assisted coughing). However, these can be difficult for frail patients and require a therapist or carer to help. In order to optimise cough, the lungs need to be maximally inflated. To assist patients in making a large inspiratory effort, a manual resuscitator (Ambu bag) can be used (breath-stacking technique - figure 4 ). An alternative modern approach is to use a mechanical device called a Mechanical In-Exsufflator (MI-E) or CoughAssist machine ( figure 5 ). This delivers a positive pressure (insufflation) via a face mask to allow maximal lung expansion, followed by a negative pressure (exsufflation). The expiratory flow generated by the device brings airway secretions up to the throat from where they can be cleared. Maximal lung expansion using these techniques may reduce the work of breathing as lungs are less distensible at lower volumes. MI-E produces a greater increase in PCF compared with other modes of cough augmentation. 25 The volume of air exsufflated and PCF achievable using MI-E are comparable with those expelled during normal adult coughing. The American Academy of Neurology suggests that MI-E is an option to clear airway secretions in patients with reduced PCF, particularly during an acute chest infection. However, there is only weak evidence for MI-E (level C). MI-E equipment is relatively expensive (machines cost £4000) and is not currently funded within the NHS due to lack of proven benefit. We therefore need appropriately designed randomised controlled trials of this intervention in MND patients.
Although there are no evidence-based guidelines for the management of impaired cough in different phases of the disease, box 2 summarises observations from the existing literature. [26] [27] [28] [29] [30] Most patients can attain assisted PCF of >160 l/min, except those with severe bulbar disease. 31 Assisted cough manoeuvres may not help patients with severe bulbar dysfunction, as glottis closure is crucial to generate high pressure within the lungs before the expulsive phase of the cough. With progression of bulbar dysfunction, the upper airway collapses during inspiration and expiration. This may render MI-E ineffective and risks aspiration, potentially leading to pneumonia and respiratory failure.
Role of invasive ventilation-tracheostomy ventilation
Invasive ventilation involves a tracheostomy tube to deliver air into the lungs and clear secretions from the upper airways. Tracheostomy ventilation (TV) is an option to ventilate patients with severe bulbar dysfunction who cannot tolerate NIV. TV may also help even in successful NIV users when, as the respiratory and bulbar muscle weakness progresses, non-invasive effective ventilation becomes difficult. Apart from being an option for ventilation, tracheostomy may also help patients with severe bulbar dysfunction to protect the airway from recurrent aspiration of saliva. A recent study involving 38 patients with MND (19 spinal/19 bulbar onset) who had tracheostomy, reported 1-year survival of 79%, with a mean survival of 10.4 months. 32 The time from MND onset to tracheostomy was 41.3±42.4 months. Twenty patients had used NIV previously at home. The authors did not assess patients' and carers' quality of life; however, quality-of-life studies after tracheostomy report positive patient views about tracheostomy and acceptable quality of life. 33 34 TV is usually provided with a volume-cycled ventilator through an uncuffed tube. TV does not involve a face mask (hence, no risk of claustrophobia or facial discomfort) and allows direct suctioning of secretions. However, there are several potential problems such as bleeding and infection at the tracheostomy site (tracheitis), recurrent pneumonia, tracheo-oesophgeal fistula, and it also risks the patient being trapped in a paralysed body-'locked-in state' or 'ventilator entrapment'. With an uncuffed tube, patients may continue to talk and eat, but they risk aspiration. In addition, air leaks may cause discomfort or compromise the effectiveness of mechanical ventilation. Uncuffed tubes may need replacing by cuffed tubes when effective ventilation cannot be achieved despite increasing the ventilator volumes. With a cuffed tube, the patient loses ability to speak; communication difficulties will further increase when eye movements are also lost. Furthermore, a cuffed tracheostomy tube risks tracheal necrosis from cuff over-inflation. TV also requires extensive resources (24-h nursing care and frequent hospitalisations) and reduces carers' quality of life. 35 It may prolong life despite increasing disability and dependency; thus, quality of life may not be sustained in the advanced stages of the disease. It should only be undertaken after a full discussion of the pros and cons with the patient and the carer. Unplanned and unwanted emergency tracheostomy should be avoided by discussing this option with the patient and their relatives at an earlier stage and documenting the decision in an advanced directive. In the USA, few MND patients take this option due to the generally negative attitude of the physicians and lack of coverage for invasive ventilation by most health insurance policies. Similarly, TV in MND is not encouraged in Europe considering the progressive and incurable nature of MND, and the high cost involved in caring for a patient with tracheostomy. 36 However, TV is the predominant form of ventilation offered to the patients with MND in Japan, and the cost is fully covered by the government and medical insurance. According to one Japanese survey, 30% of patients in Japan took this option. 37 In the UK, tracheostomy is mostly performed only following emergency endotracheal intubation, during a life-threatening acute respiratory deterioration. Rarely, the diagnosis of MND may have not been made and patients may present to the emergency department with respiratory failure of unknown cause and undergo tracheostomy. Such undiagnosed patients may have severe diaphragmatic weakness, with subtle limb signs. These patients have difficulty weaning from the ventilator, but it is important to try to switch them to non-invasive ventilation.
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Role of diaphragm pacing
Diaphragm pacing (DP) gives assisted ventilation using intramuscular electrical stimulation of the diaphragm to produce contractions. It was developed to provide ventilator support to patients with high spinal cord injury. 39 In these patients, it allowed reduced time on mechanical ventilation, or removed the need for this intervention. Diaphragm pacing has been used in patients with MND and respiratory failure. However, there are limited data about its efficacy in these patients and the technique is still experimental. The modern NeuRx RA/4 DP system comprises 4 electrodes implanted laparoscopically on to the abdominal surface of the diaphragm (two in each hemi-diaphragm). The surgeon establishes the best site for electrode placement by mapping the diaphragm to locate the phrenic motor points. The system only works if the diaphragm muscle retains some degree of innervation. The leads are tunnelled subcutaneously to a suitable exit site, usually in the upper abdomen. A pocket-size battery-operated external stimulator delivers the stimulus pulses and provides respiratory movements (figure 6). The equipment and surgery cost £16 000. Onders et al reported that general anaesthesia is safe in patients with MND having laparoscopic surgery for diaphragm pacing. 40 They reported diaphragm pacing in 51 patients with FVC readings ranging from 20% to 87% of predicted, with no failure to extubate, or 30-day mortality. Diaphragm pacing has potential advantages over mechanical ventilation. Most patients can eat, talk and walk freely while being paced. However, patients need careful post-implantation follow-up.
The US Food and Drug Administration approved an ongoing clinical trial of diaphragm pacing in MND, which will inform about its safety, tolerability and efficacy. A randomised controlled clinical trial (DiPALS) underway in the UK will evaluate diaphragm pacing further in patients with MND. The management guidelines on diaphragm pacing in MND await the conclusion of these trials.
Nutrition in respiratory muscle function
Clinicians must pay careful attention to nutritional management to optimise respiratory function. Patients with MND are particularly predisposed to malnutrition for several reasons, including dysphagia, fear of choking and aspiration, inability to feed themselves and high resting metabolic rate. Malnutrition may affect respiratory muscle function in several ways: reduced respiratory muscle mass and strength through atrophy of the type II fibres, poor availability of energy substrates for muscle metabolism, blunting of ventilatory drive and impaired cell-mediated and humoural immunity and, hence, reduced resistance to chest infections.
Conclusion
Respiratory muscle function significantly predicts survival and quality of life in patients with MND. The management of respiratory symptoms and maintenance of lung compliance are particularly important. NIV prolongs life and maintains quality of life in patients with MND. NIV requires a specialist service with ability to monitor and detect hypoventilation, to start NIV with the optimal machine and interface and optimised settings, to monitor the effectiveness of NIV and to manage complications. It is essential to have effective communication with the patient and family throughout the service. It is particularly important that the patient understands the role of NIV, and that the clinician records their wishes early on regarding management of intercurrent illness, increasing reliance of NIV and end-of-life care. The recent NICE guidelines concluded that such a service is a cost-effective use of NHS resources. 
